These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 33803955)

  • 1. Prognostic Value of microRNA-221/2 and 17-92 Families in Primary Glioblastoma Patients Treated with Postoperative Radiotherapy.
    Schnabel E; Knoll M; Schwager C; Warta R; Mock A; Campos B; König L; Jungk C; Wick W; Unterberg A; Debus J; Herold-Mende C; Abdollahi A
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33803955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a multidimensional transcriptome signature for survival prediction of postoperative glioblastoma multiforme patients.
    Gao WZ; Guo LM; Xu TQ; Yin YH; Jia F
    J Transl Med; 2018 Dec; 16(1):368. PubMed ID: 30572911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
    Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
    Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low serum level of miR-485-3p predicts poor survival in patients with glioblastoma.
    Wang ZQ; Zhang MY; Deng ML; Weng NQ; Wang HY; Wu SX
    PLoS One; 2017; 12(9):e0184969. PubMed ID: 28931080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ribosomal Proteins RPS11 and RPS20, Two Stress-Response Markers of Glioblastoma Stem Cells, Are Novel Predictors of Poor Prognosis in Glioblastoma Patients.
    Yong WH; Shabihkhani M; Telesca D; Yang S; Tso JL; Menjivar JC; Wei B; Lucey GM; Mareninov S; Chen Z; Liau LM; Lai A; Nelson SF; Cloughesy TF; Tso CL
    PLoS One; 2015; 10(10):e0141334. PubMed ID: 26506620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A 4-miRNAs signature predicts survival in glioblastoma multiforme patients.
    Yuan GQ; Wei NL; Mu LY; Wang XQ; Zhang YN; Zhou WN; Pan YW
    Cancer Biomark; 2017 Dec; 20(4):443-452. PubMed ID: 28869437
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
    Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
    Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic risk model construction and molecular marker identification in glioblastoma multiforme based on mRNA/microRNA/long non-coding RNA analysis using random survival forest method.
    Wang H; Liu D; Yang J
    Neoplasma; 2019 May; 66(3):459-469. PubMed ID: 30784292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR-504 suppresses mesenchymal phenotype of glioblastoma by directly targeting the FZD7-mediated Wnt-β-catenin pathway.
    Liu Q; Guan Y; Li Z; Wang Y; Liu Y; Cui R; Wang Y
    J Exp Clin Cancer Res; 2019 Aug; 38(1):358. PubMed ID: 31419987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation and isocitrate dehydrogenase-1 (IDH-1) mutation in glioblastoma multiforme patients: A single-center experience in the Middle East region.
    Ayoub Z; Geara F; Najjar M; Comair Y; Khoueiry-Zgheib N; Khoueiry P; Mahfouz R; Boulos FI; Kamar FG; Andraos T; Saadeh F; Kreidieh F; Abboud M; Skaf G; Assi HI
    Clin Neurol Neurosurg; 2019 Jul; 182():92-97. PubMed ID: 31108342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-target cross-talks: Key players in glioblastoma multiforme.
    Toraih EA; Aly NM; Abdallah HY; Al-Qahtani SA; Shaalan AA; Hussein MH; Fawzy MS
    Tumour Biol; 2017 Nov; 39(11):1010428317726842. PubMed ID: 29110584
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-106a is an independent prognostic marker in patients with glioblastoma.
    Zhao S; Yang G; Mu Y; Han D; Shi C; Chen X; Deng Y; Zhang D; Wang L; Liu Y; Hou X; Wang C; Wu J; Liu H; Wang L; Zhang G; Qi J; Fang X; Shi C; Ai J
    Neuro Oncol; 2013 Jun; 15(6):707-17. PubMed ID: 23416698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. O
    Alassiri AH; Alkhaibary A; Al-Sarheed S; Alsufani F; Alharbi M; Alkhani A; Aloraidi A
    Ann Saudi Med; 2019; 39(6):410-416. PubMed ID: 31804140
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An miR-340-5p-macrophage feedback loop modulates the progression and tumor microenvironment of glioblastoma multiforme.
    Liu Y; Li X; Zhang Y; Wang H; Rong X; Peng J; He L; Peng Y
    Oncogene; 2019 Dec; 38(49):7399-7415. PubMed ID: 31427735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Up-regulation of miR-370-3p restores glioblastoma multiforme sensitivity to temozolomide by influencing MGMT expression.
    Gao YT; Chen XB; Liu HL
    Sci Rep; 2016 Sep; 6():32972. PubMed ID: 27595933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of prognostic biomarkers in glioblastoma using a long non-coding RNA-mediated, competitive endogenous RNA network.
    Cao Y; Wang P; Ning S; Xiao W; Xiao B; Li X
    Oncotarget; 2016 Jul; 7(27):41737-41747. PubMed ID: 27229531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging role of miRNAs as liquid biopsy markers for prediction of glioblastoma multiforme prognosis.
    Swellam M; Bakr NM; El Magdoub HM; Hamza MS; Ezz El Arab LR
    J Mol Neurosci; 2021 Apr; 71(4):836-844. PubMed ID: 32989634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
    Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
    Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
    Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
    Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Galectin-1 is a poor prognostic factor in patients with glioblastoma multiforme after radiotherapy.
    Chou SY; Yen SL; Huang CC; Huang EY
    BMC Cancer; 2018 Jan; 18(1):105. PubMed ID: 29378529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.